Clarivate PLC (NYSE:CLVT) Given Average Recommendation of “Reduce” by Analysts

Shares of Clarivate PLC (NYSE:CLVT) have received a consensus recommendation of “Reduce” from the eight brokerages that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $3.2167.

A number of research analysts have recently commented on the company. Wall Street Zen upgraded Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Citigroup cut their price target on Clarivate from $4.25 to $2.80 and set a “neutral” rating for the company in a report on Wednesday, March 4th. Barclays cut their price target on Clarivate from $4.00 to $2.40 and set an “underweight” rating for the company in a report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Clarivate in a report on Friday, March 27th. Finally, Royal Bank Of Canada cut their price target on Clarivate from $5.00 to $3.00 and set a “sector perform” rating for the company in a report on Wednesday, February 25th.

Clarivate Stock Up 3.6%

Shares of CLVT stock opened at $2.43 on Friday. Clarivate has a 12 month low of $1.66 and a 12 month high of $4.77. The firm has a market cap of $1.55 billion, a PE ratio of -11.55 and a beta of 1.41. The stock has a 50 day moving average of $2.54 and a 200-day moving average of $2.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 0.89.

Clarivate (NYSE:CLVT) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.The company had revenue of $585.50 million during the quarter, compared to analyst estimates of $569.50 million. During the same period in the previous year, the company earned $0.14 earnings per share. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. On average, equities analysts predict that Clarivate will post 0.65 EPS for the current year.

Institutional Trading of Clarivate

A number of institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers increased its position in shares of Clarivate by 11.2% during the second quarter. Cetera Investment Advisers now owns 26,034 shares of the company’s stock valued at $112,000 after purchasing an additional 2,617 shares during the period. California State Teachers Retirement System increased its position in shares of Clarivate by 0.9% during the second quarter. California State Teachers Retirement System now owns 303,147 shares of the company’s stock valued at $1,304,000 after purchasing an additional 2,788 shares during the period. Envestnet Asset Management Inc. increased its position in shares of Clarivate by 3.9% during the third quarter. Envestnet Asset Management Inc. now owns 77,275 shares of the company’s stock valued at $296,000 after purchasing an additional 2,884 shares during the period. IFP Advisors Inc increased its position in shares of Clarivate by 8.1% during the third quarter. IFP Advisors Inc now owns 41,426 shares of the company’s stock valued at $170,000 after purchasing an additional 3,117 shares during the period. Finally, Hsbc Holdings PLC increased its position in shares of Clarivate by 4.3% during the second quarter. Hsbc Holdings PLC now owns 116,648 shares of the company’s stock valued at $500,000 after purchasing an additional 4,792 shares during the period. 85.72% of the stock is currently owned by institutional investors.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.